Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil
ONCOLOGY, vol.56, no.4, pp.297-300, 1999 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 56 Issue: 4
- Publication Date: 1999
- Doi Number: 10.1159/000011981
- Journal Name: ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.297-300
- Keywords: colorectal carcinoma, chemotherapy, cisplatin, dacarbazine, 5-fluorouracil, CANCER
- Lokman Hekim University Affiliated: No
Abstract
Twenty-six patients with metastatic colorectal cancer were given cisplatin (CDDP) and dacarbazine (DTIC), Patients who relapsed while receiving adjuvant 5-fluorouracil (FU) or had 5-FU-resistant metastatic disease were included. Median age was 52 years and the male-to-female ratio was 1. Performance status (ECOG) was 3 in 5 patients and 0-2 in the remainder. CDDP (20 mg/m(2)/day i.v.) and DTIC were given (250 mg/m(2)/day i.v.) on days 1-5. The treatment was repeated every 3 weeks until disease progression. Total response rate was 19.2% (95% confidence interval: 4.5-34.3%) with one clinical complete response (3.8%) and 4 partial responses (15.4%). Median response duration was 5 months. Median survival for the whole group and for responders was 6 and 8 months, respectively. In conclusion, CDDP + DTIC combination has modest activity in patients with colorectal cancer resistant to 5-FU treatment.